Duloxetine for Generalized Anxiety Disorder
Eli Lilly has announced the FDA’s approval of the antidepressant duloxetine HCl (Cymbalta drug) in patients with Generalized Anxiety Disorder (GAD). GAD affects more than 6.5 million American adults each year.
In three randomized, double-blind, placebo-controlled studies of more than 800 non-depressed adults with GAD, the drug significantly improved core anxiety symptoms, compared with placebo. Treated patients reported an improved ability to perform everyday activities.
Duloxetine generic is also approved for adults with Major Depressive Disorder and diabetic peripheral neuropathic pain.
